StockNews.AI
MXCT
StockNews.AI
131 days

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

1. MaxCyte will release Q1 2025 financial results on May 7, 2025. 2. A conference call will follow the earnings report at 4:30 p.m. ET. 3. The ExPERT platform supports the growing cell therapy market. 4. MaxCyte’s technology advancements could enhance cell therapeutics' commercialization. 5. Investors encouraged to register for the upcoming earnings call.

Earnings
-7.51%Current Return
VS
-4.38%S&P 500
$2.5304/10 02:14 AM EDTEvent Start
$2.3404/11 08:55 AM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results can positively influence investor sentiment. Strong demand for cell therapy technologies may boost future earnings.

How important is it?

Financial results and earnings calls create investor interest and market movement potentials. The focus on cell therapy aligns with broader healthcare trends, enhancing implications.

Why Short Term?

The immediate effect of earnings reports typically influences stock prices shortly after announcements.

Related Companies

CRSPNSTGEDIT
April 10, 2025 02:00 ET  | Source: MaxCyte, Inc ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/. About MaxCyte At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@maxcyte.com US Media RelationsSpectrum ScienceJordan Vinesjvines@spectrumscience.com +1 540-629-3137 Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@icrhealthcare.com

Related News